Get the Stockscreener App
2.82
1.44%
0.04
After Hours:
2.74
-0.08
-2.84%
Cabaletta Bio Inc stock is traded at $2.82, with a volume of 1.35M.
It is up +1.44% in the last 24 hours and down -18.97% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$2.78
Open:
$2.77
24h Volume:
1.35M
Relative Volume:
0.46
Market Cap:
$271.47M
Revenue:
-
Net Income/Loss:
$-167.86M
P/E Ratio:
-1.2296
EPS:
-2.2935
Net Cash Flow:
$-132.31M
1W Performance:
-7.24%
1M Performance:
-18.97%
6M Performance:
+19.49%
1Y Performance:
+79.62%
1-Day Range:
$2.71
$2.88
1-Week Range:
$2.64
$3.245
52-Week Range:
$0.9857
$3.78
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.82 | 267.62M | 0 | -167.86M | -132.31M | -2.2935 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Aug Retail: What is Cabaletta Bio Incs P E ratio telling usPortfolio Profit Report & Capital Efficient Trading Techniques - baoquankhu1.vn
Guggenheim Forecasts Strong Price Appreciation for Cabaletta Bio (NASDAQ:CABA) Stock - MarketBeat
Morgan Stanley Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $13.00 - MarketBeat
Analyst Michael Ulz Lowers Price Target for Cabaletta Bio (CABA) to $13 | CABA Stock News - GuruFocus
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $13 to $14 - Moomoo
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Jefferies reiterates Buy on Cabaletta Bio stock, $14 target By Investing.com - Investing.com Australia
Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley - TipRanks
Jefferies reiterates Buy on Cabaletta Bio stock, $14 target - Investing.com UK
William Blair reiterates Outperform on Cabaletta Bio stock By Investing.com - Investing.com Canada
CABA Advances with Innovative Therapeutic Approaches - GuruFocus
Guggenheim raises Cabaletta Bio stock price target on trial progress By Investing.com - Investing.com Australia
Guggenheim raises Cabaletta Bio stock price target on trial progress - Investing.com
Cabaletta Bio Reports 2025 Financial Results, Highlights Progress on Rese-cel CAR-T Cell Therapy and Upcoming Clinical Milestones - Minichart
Jefferies Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Cabaletta Bio 2024 Annual Report: Engineered T Cell Therapies, Competitive Landscape, and Intellectual Property Strategies for Autoimmune Diseases - Minichart
Cabaletta Bio reports Q4 EPS (40c), consensus (47c) - TipRanks
Cabaletta Bio (CABA) Exceeds Q4 EPS Expectations - GuruFocus
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Cabaletta Bio Updates Rese-cel Programs and Financial Outlook - TipRanks
Cabaletta Bio (NASDAQ:CABA) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Cabaletta Bio 10-K: Net loss $167.9M; Cash resources support into Q4 2026 - TradingView
Cabaletta Bio (NASDAQ: CABA) details 2025 results and advances rese-cel trials - Stock Titan
Cabaletta Bio : Corporate Presentation - marketscreener.com
[10-K] Cabaletta Bio, Inc. Files A... - Stock Titan
CABA: Clinical and manufacturing advances drive progress, with strong cash runway into late 2026 - TradingView
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business ... - Caledonian Record
Cabaletta starts automated cell-therapy manufacturing, targets thousands a year - Stock Titan
Cabaletta Bio (CABA) Projected to Post Earnings on Monday - MarketBeat
Quarterly Trades: Is Cabaletta Bio Inc stock a smart retirement pickPortfolio Risk Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn
Cabaletta Bio to Present at Jefferies Global Healthcare Conference 2025 - MSN
If You Invested $1,000 in Cabaletta Bio, Inc. (CABA) - Stock Titan
Breakout Watch: Can MURA ride the EV wave2026 Opening Moves & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
HC Wainwright & Co. Reiterates Cabaletta Bio (CABA) Buy Recommendation - MSN
Gap Down: Can DCTH beat the S P 5002026 Winners & Losers & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Heights Capital Management Inc. Sells 1,059,904 Shares of Cabaletta Bio, Inc. $CABA - MarketBeat
CABA Stock Price, Quote & Chart | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
Merger Talk: Will Cabaletta Bio Inc announce a stock splitInflation Watch & Long-Term Safe Return Strategies - baoquankhu1.vn
Quarterly Earnings: Will Bowman Consulting Group Ltd benefit from seasonality2026 Top Gainers & Weekly Breakout Watchlists - baoquankhu1.vn
What are Cabaletta Bio Incs recent SEC filings showingWeekly Risk Report & Breakout Confirmation Trade Signals - baoquankhu1.vn
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy - MSN
Cabaletta Bio (CABA) upgraded to buy: Here's what you should know - MSN
Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference - MarketBeat
Day Trade: What are Cabaletta Bio Inc.’s recent SEC filings showingJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Aug Sectors: Is Cabaletta Bio Incs ROE strong enough2025 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Cabaletta Bio takes spotlight at Guggenheim Summit as autoimmune bet advances - MSN
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday - MarketBeat
CABA SEC FilingsCabaletta Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
TD Cowen Health Care Conference - marketscreener.com
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):